These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 21655990)

  • 1. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.
    Hadad S; Iwamoto T; Jordan L; Purdie C; Bray S; Baker L; Jellema G; Deharo S; Hardie DG; Pusztai L; Moulder-Thompson S; Dewar JA; Thompson AM
    Breast Cancer Res Treat; 2011 Aug; 128(3):783-94. PubMed ID: 21655990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial.
    Hadad SM; Coates P; Jordan LB; Dowling RJ; Chang MC; Done SJ; Purdie CA; Goodwin PJ; Stambolic V; Moulder-Thompson S; Thompson AM
    Breast Cancer Res Treat; 2015 Feb; 150(1):149-55. PubMed ID: 25682077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study.
    Niraula S; Dowling RJ; Ennis M; Chang MC; Done SJ; Hood N; Escallon J; Leong WL; McCready DR; Reedijk M; Stambolic V; Goodwin PJ
    Breast Cancer Res Treat; 2012 Oct; 135(3):821-30. PubMed ID: 22933030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study.
    Dowling RJ; Niraula S; Chang MC; Done SJ; Ennis M; McCready DR; Leong WL; Escallon JM; Reedijk M; Goodwin PJ; Stambolic V
    Breast Cancer Res; 2015 Mar; 17(1):32. PubMed ID: 25849721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.
    Bonanni B; Puntoni M; Cazzaniga M; Pruneri G; Serrano D; Guerrieri-Gonzaga A; Gennari A; Trabacca MS; Galimberti V; Veronesi P; Johansson H; Aristarco V; Bassi F; Luini A; Lazzeroni M; Varricchio C; Viale G; Bruzzi P; Decensi A
    J Clin Oncol; 2012 Jul; 30(21):2593-600. PubMed ID: 22564993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer.
    Sabine VS; Sims AH; Macaskill EJ; Renshaw L; Thomas JS; Dixon JM; Bartlett JM
    Breast Cancer Res Treat; 2010 Jul; 122(2):419-28. PubMed ID: 20480226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study.
    Campagnoli C; Pasanisi P; Abbà C; Ambroggio S; Biglia N; Brucato T; Colombero R; Danese S; Donadio M; Venturelli E; Zito G; Berrino F
    Clin Breast Cancer; 2012 Jun; 12(3):175-82. PubMed ID: 22607767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial.
    Mitsuhashi A; Kiyokawa T; Sato Y; Shozu M
    Cancer; 2014 Oct; 120(19):2986-95. PubMed ID: 24917306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer.
    Laskov I; Drudi L; Beauchamp MC; Yasmeen A; Ferenczy A; Pollak M; Gotlieb WH
    Gynecol Oncol; 2014 Sep; 134(3):607-14. PubMed ID: 24972190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
    J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer.
    Joshua AM; Zannella VE; Downes MR; Bowes B; Hersey K; Koritzinsky M; Schwab M; Hofmann U; Evans A; van der Kwast T; Trachtenberg J; Finelli A; Fleshner N; Sweet J; Pollak M
    Prostate Cancer Prostatic Dis; 2014 Sep; 17(3):252-8. PubMed ID: 24861559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers.
    Yee LD; Williams N; Wen P; Young DC; Lester J; Johnson MV; Farrar WB; Walker MJ; Povoski SP; Suster S; Eng C
    Clin Cancer Res; 2007 Jan; 13(1):246-52. PubMed ID: 17200362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity and insulin resistance in breast cancer--chemoprevention strategies with a focus on metformin.
    Goodwin PJ; Stambolic V
    Breast; 2011 Oct; 20 Suppl 3():S31-5. PubMed ID: 22015290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
    Bjarnadottir O; Romero Q; Bendahl PO; Jirström K; Rydén L; Loman N; Uhlén M; Johannesson H; Rose C; Grabau D; Borgquist S
    Breast Cancer Res Treat; 2013 Apr; 138(2):499-508. PubMed ID: 23471651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study.
    Soliman PT; Zhang Q; Broaddus RR; Westin SN; Iglesias D; Munsell MF; Schmandt R; Yates M; Ramondetta L; Lu KH
    Gynecol Oncol; 2016 Dec; 143(3):466-471. PubMed ID: 27745917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Metformin does not suppress the aromatase expression in breast cancer tissue of patients with concurrent type 2 diabetes].
    Bershteĭn LM; Turkevich EA; Boiarkina MP
    Vopr Onkol; 2012; 58(2):194-8. PubMed ID: 22774523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin.
    Wysocki PJ; Wierusz-Wysocka B
    Expert Rev Mol Diagn; 2010 May; 10(4):509-19. PubMed ID: 20465505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting AMPK: a new therapeutic opportunity in breast cancer.
    Hadad SM; Fleming S; Thompson AM
    Crit Rev Oncol Hematol; 2008 Jul; 67(1):1-7. PubMed ID: 18343152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of metformin on weight loss in women with gestational diabetes: a pilot randomized, placebo-controlled trial.
    Refuerzo JS; Viteri OA; Hutchinson M; Pedroza C; Blackwell SC; Tyson JE; Ramin SM
    Am J Obstet Gynecol; 2015 Mar; 212(3):389.e1-9. PubMed ID: 25526875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer.
    Guppy A; Jamal-Hanjani M; Pickering L
    Future Oncol; 2011 Jun; 7(6):727-36. PubMed ID: 21675836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.